Incyte (INCY) Other Non-Current Liabilities (2013 - 2026)
Incyte (INCY) posted Other Non-Current Liabilities of $126.6 million for Q1 2026, down 23.41% on a QoQ basis from $165.3 million in Q4 2025, and down 27.91% year-over-year from $175.6 million in Q1 2025.
Incyte (INCY) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Incyte's Other Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $126.6 million for Q1 2026.
- Quarterly Other Non-Current Liabilities fell 27.91% year-over-year to $126.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $126.6 million (down 27.91% YoY) and the FY2025 annual result came in at $165.3 million, down 1.36% from the prior year.
- Other Non-Current Liabilities was $126.6 million for Q1 2026 at Incyte, down from $165.3 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $204.1 million in Q1 2022 and bottomed at $74.7 million in Q3 2022.
- A 5-year average of $148.6 million and a median of $151.1 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Peak annual rise in Other Non-Current Liabilities reached 274.8% in 2022, while the deepest fall reached 65.27% in 2022.
- Incyte's Other Non-Current Liabilities stood at $184.5 million in 2022, then retreated by 19.14% to $149.2 million in 2023, then advanced by 12.33% to $167.5 million in 2024, then retreated by 1.36% to $165.3 million in 2025, then fell by 23.41% to $126.6 million in 2026.
- Business Quant data shows INCY's Other Non-Current Liabilities at $126.6 million in Q1 2026, $165.3 million in Q4 2025, and $171.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Incyte | 23.33 Bn | 19.32 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 126.59 Mn |
| Dec 31, 2025 | 165.27 Mn |
| Sep 30, 2025 | 171.18 Mn |
| Jun 30, 2025 | 179.91 Mn |
| Mar 31, 2025 | 175.59 Mn |
| Dec 31, 2024 | 167.54 Mn |
| Sep 30, 2024 | 166.67 Mn |
| Jun 30, 2024 | 142.10 Mn |
| Mar 31, 2024 | 151.11 Mn |
| Dec 31, 2023 | 149.15 Mn |
| Sep 30, 2023 | 133.07 Mn |
| Jun 30, 2023 | 139.81 Mn |
| Mar 31, 2023 | 118.41 Mn |
| Dec 31, 2022 | 184.46 Mn |
| Sep 30, 2022 | 74.68 Mn |
| Jun 30, 2022 | 76.06 Mn |
| Mar 31, 2022 | 204.13 Mn |
| Dec 31, 2021 | 70.41 Mn |
| Sep 30, 2021 | 62.31 Mn |
| Jun 30, 2021 | 219.01 Mn |